

**Oklahoma Health Care Authority
Drug Utilization Review Board**

(DUR Board)

Meeting – October 12, 2011 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. September 14, 2011 DUR Minutes – Vote
 - B. September 15, 2011 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for July 2011
 - B. Retrospective Drug Utilization Review Response for May 2011
 - C. Medication Coverage Activity Audit for September 2011
 - D. Pharmacy Help Desk Activity Audit for September 2011

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize Firazyr[®] – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

6. **60 Day Notice to Prior Authorize Multiple Sclerosis Medications – See Appendix D.**
 - A. Member Demographics
 - B. Market Share
 - C. Cost Comparison
 - D. Safety and Efficacy
 - E. Economic Impact
 - F. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Keast, Dr. Muchmore, Chairman

7. **30 Day Notice to Prior Authorize Biologic Products for the Treatment of Rheumatoid Arthritis, Crohn's Disease, Plaque Psoriasis, and Ankylosing Spondylitis – See Appendix E.**
 - A. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Pediculicides and 30 Day Notice to Prior Authorize Natroba™ – See Appendix F.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Update
 - E. COP Recommendations
 - F. Utilization Details
 - G. Natroba™ Product Details

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Ocular Antibiotics and 30 Day Notice to Prior Authorize Moxeza™ – See Appendix G.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Update
 - E. COP Recommendations
 - F. Moxeza™ Product Details

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

10. **Action Item – Annual Review of Antihypertensives and 30 Day Notice to Prior Authorize Amturnide™ and Edarbi™ – See Appendix H.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Update
 - E. COP Recommendations
 - F. Amturnide™ and Edarbi™ Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

11. **Action Item – Annual Review of Antidepressants and 30 Day notice to Prior Authorize Viibryd® – See Appendix I.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Update
 - E. COP Recommendations
 - F. Utilization Details
 - G. Viibryd® Product Details

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

12. **FDA and DEA Updates – See Appendix J.**

13. **Future Business**

- A. Annual Review of Statins
- B. Annual Review of Narcotics
- C. New Product Reviews
- D. Medical Product Reviews

14. **Adjournment**